Progyny/$PGNY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Progyny
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
- Ticker
- $PGNY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 846
- Headquarters
- New York, United States
- Website
- www.progyny.com
Progyny Metrics
BasicAdvanced
$2.3B
32.42
$0.91
0.99
-
Price and volume
Market cap
$2.3B
Beta
0.99
52-week high
$33.07
52-week low
$16.10
Average daily volume
1M
Financial strength
Current ratio
2.137
Quick ratio
2.059
Long term debt to equity
0.05
Total debt to equity
0.05
Profitability
EBITDA (TTM)
125.572
Gross margin (TTM)
24.57%
Net profit margin (TTM)
6.00%
Operating margin (TTM)
9.14%
Effective tax rate (TTM)
34.38%
Revenue per employee (TTM)
$1,550,000
Management effectiveness
Return on assets (TTM)
10.14%
Return on equity (TTM)
16.24%
Valuation
Price to earnings (TTM)
32.422
Price to revenue (TTM)
1.853
Price to book
4.98
Price to tangible book (TTM)
5.28
Price to free cash flow (TTM)
13.617
Free cash flow yield (TTM)
7.34%
Free cash flow per share (TTM)
2.16
Growth
Revenue change (TTM)
5.54%
Earnings per share change (TTM)
55.39%
3-year revenue growth (CAGR)
11.04%
3-year earnings per share growth (CAGR)
22.78%
What the Analysts think about Progyny
Analyst ratings (Buy, Hold, Sell) for Progyny stock.
Analyst projections of the future price of Progyny stock.
Bulls say / Bears say
Second-quarter gross margin widened to 25.5% from 23.7%, while net income rose to $28.1 million from $17.1 million. That points to improving profitability alongside growth. (Progyny)
Progyny said its current selling season is pacing towards a potential record, with commitments and expected decisions pointing to 1.2 million new covered lives launching by the first half of 2027. If delivered, that would add a meaningful source of growth. (GlobeNewswire)
The company serves 7.2 million lives against a stated 106 million-life core market, while Progyny Select could open access to a further 50 million smaller-employer lives. This offers longer-term expansion potential, although the new product is not expected to add much in 2027. (OpenCapital, Stock Analysis)
ART treatment cycles were almost flat year on year despite average covered membership rising by about 6.6%, and management flagged a more pronounced summer slowdown in member activity. If that softness persists, it could constrain revenue growth. (Progyny)
The loss of a large client continues to weigh on reported comparisons: second-quarter revenue grew 5.3%, versus 11.0% excluding that former client's prior-year revenue. That makes headline growth look notably weaker than the underlying business trend. (Progyny)
Pharmacy benefit revenue grew just 1.2% in the second quarter, and Progyny said it absorbed some cost increases to support clients. Continued cost pressure could hold back growth or profitability in this part of the business. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
Progyny Financial Performance
Revenues and expenses
Progyny Earnings Performance
Company profitability
Upcoming events
No upcoming events
Progyny News
AllArticlesVideos
Funds containing Progyny
AllUSDEURGBP
Fund name | Fund size | $PGNY weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.12% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.12% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.07% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.